The relationship between clinical pharmacokinetics of aripiprazole and CYP2D6 genetic polymorphism: Effects of CYP enzyme inhibition by coadministration of paroxetine or fluvoxamine

European Journal of Clinical Pharmacology

Volumn 68, Issue 1, 2012, Pages 29-37

  Azuma, Junichi ^a   Hasunuma, Tomoko ^b   Kubo, Masanori ^c   Miyatake, Masaya ^c   Koue, Toshiko ^c   Higashi, Koushi ^c   Fujiwara, Tsutomu ^c   Kitahara, Sachiko ^c   Katano, Tamiki ^c   Hara, Sumiko ^c  

^a HYOGO COLLEGE OF MEDICINE   (Japan)

^b KITASATO UNIVERSITY   (Japan)

^c OTSUKA PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Aripiprazole; CYP2D6 polymorphism; Drug interaction; Fluvoxamine; Paroxetine; Pharmacokinetics

Indexed keywords

ARIPIPRAZOLE; CYTOCHROME P450 2D6; FLUVOXAMINE; FLUVOXAMINE MALEATE; PAROXETINE;

ADULT; ALLELE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CYP2D6 GENE; DRUG CLEARANCE; ENZYME INHIBITION; GENE PRODUCT; GENETIC POLYMORPHISM; GENOTYPE; GENOTYPING TECHNIQUE; HALF LIFE TIME; HUMAN; HUMAN EXPERIMENT; JAPANESE; MALE; MAXIMUM PLASMA CONCENTRATION; METABOLIC ACTIVATION; NORMAL HUMAN; OPEN STUDY; PRIORITY JOURNAL; REPEATED DRUG DOSE; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION;

ADULT; ANTIPSYCHOTIC AGENTS; BIOTRANSFORMATION; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 CYP3A; DRUG INTERACTIONS; ENZYME INHIBITORS; FLUVOXAMINE; GENETIC ASSOCIATION STUDIES; HALF-LIFE; HUMANS; JAPAN; MALE; METABOLIC CLEARANCE RATE; PAROXETINE; PIPERAZINES; POLYMORPHISM, GENETIC; QUINOLONES; SEROTONIN 5-HT2 RECEPTOR ANTAGONISTS; SEROTONIN UPTAKE INHIBITORS; YOUNG ADULT;

EID: 84857045270     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-011-1094-4     Document Type: Article

References (25)

1. Y Oshiro S Sato N Kurahashi T Tanaka T Kikuchi K Tottori Y Uwahodo T Nishi 1998 Novel antipsychotic agents with dopamine autoreceptor agonist properties: synthesis and pharmacology of 7-[4-(4-phenyl-1-piperazinyl)butoxy]- 3,4-dihydro-2(1H)-quinolinone derivatives J Med Chem 41 658 667 9513593 10.1021/jm940608g 1:CAS:528:DyaK1cXosFaqtw%3D%3D (Pubitemid 28114874)
2. Otsuka Pharmaceutical Co, Ltd (2009) Package insert of Abilify® (aripiprazole, U.S.), July 2009 revision. Otsuka, Tokyo
3. E Perucca G Gatti E Spina 1994 Clinical pharmacokinetics of fluvoxamine Clin Pharmacokinet 27 175 190 7988100 10.2165/00003088-199427030-00002 1:CAS:528:DyaK2cXmsVGjtbs%3D (Pubitemid 24280231)
4. BA Sproule CA Naranjo KE Brenmer PC Hassan 1997 Selective serotonin reuptake inhibitors and CNS drug interactions. A critical review of the evidence Clin Pharmacokinet 33 454 471 9435993 10.2165/00003088-199733060-00004 1:CAS:528:DyaK1cXjtlGqtA%3D%3D (Pubitemid 28014515)
5. U Jeppesen LF Gram K Vistisen S Loft HE Poulsen K Brøsen 1996 Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine Eur J Clin Pharmacol 51 73 78 8880055 10.1007/s002280050163 1:CAS:528:DyaK28Xms1Klt7g%3D (Pubitemid 26300937)
6. K Venkatakrishnan RS Obach 2005 In vitro-in vivo extrapolation of CYP2D6 inactivation by paroxetine: prediction of nonstationary pharmacokinetics and drug interaction magnitude Drug Metab Dispos 33 845 852 15788540 10.1124/dmd.105.004077 1:CAS:528:DC%2BD2MXksleks7s%3D (Pubitemid 40686639)
7. J van Harten 1995 Overview of the pharmacokinetics of fluvoxamine Clin Pharmacokinet 29 Suppl 1 1 9 8846617 10.2165/00003088-199500291-00003
8. JC Fleishaker LK Hulst 1994 A pharmacokinetic and pharmacodynamic evaluation of the combined administration of alprazolam and fluvoxamine Eur J Clin Pharmacol 46 35 39 8005185 10.1007/BF00195913 1:CAS:528:DyaK2cXlvFGjsr4%3D (Pubitemid 24067586)
9. P Damkier LL Hansen K Brøsen 1999 Effect of fluvoxamine on the pharmacokinetics of quinidine Eur J Clin Pharmacol 55 451 456 10492058 10.1007/s002280050655 1:CAS:528:DyaK1MXkslyrs74%3D (Pubitemid 29399657)
10. YW Lam CL Alfaro L Ereshefsky M Miller 2003 Pharmacokinetic and pharmacodynamic interactions of oral midazolam with ketoconazole, fluoxetine, fluvoxamine, and nefazodone J Clin Pharmacol 43 1274 1282 14551182 10.1177/0091270003259216 1:CAS:528:DC%2BD3sXptFKiur0%3D (Pubitemid 37280799)
11. ZH Xu HG Xie HH Zhou 1996 In vivo inhibition of CYP2C19 but not CYP2D6 by fluvoxamine Br J Clin Pharmacol 42 518 521 8904628 10.1111/j.1365-2125.1996. tb00019.x 1:CAS:528:DyaK28XmslWru7Y%3D
12. E Spina AM Pollicino A Avenoso GM Campo E Perucca AP Caputi 1993 Effect of fluvoxamine on the pharmacokinetics of imipramine and desipramine in healthy subjects Ther Drug Monit 15 243 246 8333005 10.1097/00007691-199306000-00011 1:CAS:528:DyaK3sXmtFKluro%3D (Pubitemid 23171910)
13. M Kubo T Koue A Inaba H Takeda H Maune T Fukuda J Azuma 2005 Influence of itraconazole co-administration and CYP2D6 genotype on the pharmacokinetics of the new antipsychotic aripiprazole Drug Metab Pharmacokin 20 55 64 10.2133/dmpk.20.55 1:CAS:528:DC%2BD2MXhtFSrsL3I
14. US FDA (2002) Drug approval package, Abilify (aripiprazole) tablets. http://www.accessdata.fda.gov/drugsatfda-docs/nda/2002/21-436-Abilify.cfm
15. S Ozawa A Soyama M Saeki H Fukushima-Uesaka M Itoda S Koyano K Sai Y Ohno Y Saito J Sawada 2004 Ethnic differences in genetic polymorphisms of CYP2D6, CYP2C19, CYP3As, and MDR1/ABCB1 Drug Metab Pharmacokinet 19 83 95 15499174 10.2133/dmpk.19.83 1:CAS:528:DC%2BD2cXlsFKjs7w%3D
16. T Fukuda J Azuma 2000 Evaluation of in vivo and in vitro metabolic characteristics of CYP2D6 10 Drug Metab Pharmacokinet 15 165 170 10.2133/dmpk.15.165 1:CAS:528:DC%2BD3cXlvFSlurk%3D
17. M Kubo T Koue H Maune T Fukuda J Azuma 2007 Pharmacokinetics of aripiprazole, a new antipsychotic, following oral dosing in healthy adult Japanese volunteers: influence of CYP2D6 polymorphism Drug Metab Pharmacokinet 22 358 366 17965519 10.2133/dmpk.22.358 1:CAS:528:DC%2BD2sXhsVOgtLbF
18. K Nakamura F Goto WA Ray CB McAllister E Jacqz GR Wilkinson RA Branch 1985 Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations Clin Pharmacol Ther 38 402 408 4042523 10.1038/clpt.1985.194 1:STN:280: DyaL28%2FgtlWksQ%3D%3D (Pubitemid 16250313)
19. T Ishizaki M Eichelbaum Y Horai K Hashimoto K Chiba HJ Dengler 1987 Evidence for polymorphic oxidation of sparteine in Japanese subjects Br J Clin Pharmacol 23 482 485 3580254 1:STN:280:DyaL2s3htl2ltw%3D%3D (Pubitemid 17108181)
20. Y Horai M Nakano T Ishizaki K Ishikawa HH Zhou BI Zhou CL Liao LM Zhang 1989 Metoprolol and mephenytoin oxidation polymorphisms in Far Eastern Oriental subjects: Japanese versus mainland Chinese Clin Pharmacol Ther 46 198 207 2758729 10.1038/clpt.1989.126 1:CAS:528:DyaL1MXls1Kks7w%3D (Pubitemid 19219957)
21. M Kubo Y Mizooku Y Hirao T Osumi 2005 Development and validation of an LC-MS/MS method for the quantitative determination of aripiprazole and its main metabolite, OPC-14857, in human plasma J Chromatogr B Analyt Technol Biomed Life Sci 822 1-2 294 299 16005688 1:CAS:528:DC%2BD2MXmsVOms7o%3D (Pubitemid 40994064)
22. A Ebisawa M Hiratsuka K Sakuyama Y Konno T Sasaki M Mizugaki 2005 Two novel single nucleotide polymorphisms (SNPs) of the CYP2D6 gene in Japanese individuals Drug Metabol Pharmacokinet 20 294 299 10.2133/dmpk.20.294
23. K Sakuyama T Sasaki S Ujiie K Obata M Mizugaki M Ishikawa M Hiratsuka 2008 Functional characterization of 17 CYP2D6 allelic variants (CYP2D6.2, 10, 14A-B, 18, 27, 36, 39, 47-51, 53-55, and 57) Drug Metab Dispos 36 2460 2467 18784265 10.1124/dmd.108.023242 1:CAS:528:DC%2BD1cXhsVCltr%2FJ
24. GR Robertson J Field B Goodwin S Bierach M Tran A Lehnert C Liddle 2003 Transgenic mouse models of human CYP3A4 gene regulation Mol Pharmacol 64 42 50 12815159 10.1124/mol.64.1.42 1:CAS:528:DC%2BD3sXkvV2qtr8%3D (Pubitemid 36759816)
25. M Kubo T Koue T Fukuda J Azuma 2007 Pharmacokinetics of aripiprazole, a new antipsychotic, following oral dosing in healthy adult Japanese volunteers: influence of CYP2D6 polymorphism Drug Metab Pharmacokinet 22 358 366 17965519 10.2133/dmpk.22.358 1:CAS:528:DC%2BD2sXhsVOgtLbF